EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches

Ayesha Khan iD, Arsal Khan iD, Kuldeep Dalpat Rai iD, Anzel Saeed iD, Harsh Kumar iD, Aneesh Kumar Sangtiani iD, Tehreem Fatima iD, Muhammad Tanveer Alam, Faiza Rajput iD, Sakshi Chawla, Hussain Haider Shah iD, Humaira Kalam

Brain and Behavior · 2026-05 · 16 (5)

DOI: 10.1002/brb3.71458 ↗

At a glance

Übersichtsarbeit in Brain and Behavior, published online on 2026-04-29. Written by Ayesha Khan and 11 co-authors. Institution: Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan. Major MEDLINE topics: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Cited 2 times so far (Crossref); 175 references. The full text is freely available (open access, CC BY 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Purpose of Review : This review aims to provide a comprehensive analysis of chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on its clinical manifestations, pathophysiology, and treatment advancements, with particular emphasis on efgartigimod as a novel therapeutic agent. Recent Findings : CIDP is a chronic autoimmune disorder caused by demyelination and axonal degeneration, leading to progressive weakness and impaired sensory function. While conventional treatments, including corticosteroids, IVIg, and plasma exchange, provide symptomatic relief, their limitations include significant side effects and resistance in some cases. Efgartigimod, an FcRn blocker targeting the IgG catabolic pathway, has emerged as a promising therapy. The ADHERE study demonstrated a 61% reduction in CIDP relapses with efgartigimod, alongside improved disability scores and a favorable safety profile. Summary : CIDP presents significant diagnostic and therapeutic challenges, requiring tailored approaches to management. Efgartigimod introduces a targeted mechanism of action, offering hope for patients unresponsive to traditional therapies. Further research is needed to establish its long‐term efficacy and optimal role in CIDP treatment strategies.

Subjects

MeSH terms (MEDLINE)

Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingHumansAntibodies, Monoclonal, Humanized

Author keywords

FcRn blockersautoimmune disorderschronic inflammatory demyelinating polyneuropathydemyelinationefgartigimodemerging therapiesintravenous immunoglobulinneuropathy treatmentpathophysiologyplasma exchange

Substances

efgartigimod alfaAntibodies, Monoclonal, Humanized

Authors and institutions

  • Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
  • Shaheed Tajuddin Ahmad Medical College, Gazipur, Bangladesh.
  • Voice of Doctors Research School, Dhaka, Bangladesh.

ORCID profiles: Ayesha Khan, Arsal Khan, Kuldeep Dalpat Rai, Anzel Saeed, Harsh Kumar, Aneesh Kumar Sangtiani, Tehreem Fatima, Faiza Rajput, Hussain Haider Shah

Cite

APA

Khan, A., Khan, A., Rai, K. D., Saeed, A., Kumar, H., Sangtiani, A. K., Fatima, T., Alam, M. T., Rajput, F., Chawla, S., Shah, H. H., & Kalam, H. (2026). Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches. Brain and Behavior, 16(5). https://doi.org/10.1002/brb3.71458

Vancouver

Khan A, Khan A, Rai KD, Saeed A, Kumar H, Sangtiani AK, et al. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches. Brain and Behavior. 2026;16(5). doi:10.1002/brb3.71458

BibTeX
@article{Khan2026,
  author = {Khan, Ayesha and Khan, Arsal and Rai, Kuldeep Dalpat and Saeed, Anzel and Kumar, Harsh and Sangtiani, Aneesh Kumar and Fatima, Tehreem and Alam, Muhammad Tanveer and Rajput, Faiza and Chawla, Sakshi and Shah, Hussain Haider and Kalam, Humaira},
  title = {Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): A Comprehensive Review of Types, Pathophysiology, and Treatment Approaches},
  journal = {Brain and Behavior},
  year = {2026},
  volume = {16},
  number = {5},
  doi = {10.1002/brb3.71458}
}
Start for free →